Biolidics (SGX:8YY) Debt-to-Equity : 0.65 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biolidics Debt-to-Equity?

Biolidics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was S$0.67 Mil. Biolidics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was S$0.01 Mil. Biolidics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was S$1.04 Mil. Biolidics's debt to equity for the quarter that ended in Dec. 2024 was 0.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biolidics's Debt-to-Equity or its related term are showing as below:

SGX:8YY' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.79 Med: -0.52 Max: 1.82
Current: 0.65

During the past 10 years, the highest Debt-to-Equity Ratio of Biolidics was 1.82. The lowest was -1.79. And the median was -0.52.

SGX:8YY's Debt-to-Equity is ranked worse than
75% of 192 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs SGX:8YY: 0.65

Biolidics Debt-to-Equity Historical Data

The historical data trend for Biolidics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolidics Debt-to-Equity Chart

Biolidics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.64

1.82

-1.79

-1.02

0.65

Biolidics Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															-1.02	-1.00	-0.53	-0.34	0.65

Competitive Comparison of Biolidics's Debt-to-Equity

For the Diagnostics & Research subindustry, Biolidics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolidics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biolidics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biolidics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Biolidics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biolidics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.669	+	0.005)	/	1.036
	=	0.65

Biolidics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.669	+	0.005)	/	1.036
	=	0.65

Biolidics (SGX:8YY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biolidics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biolidics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolidics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Howard Road, No. 11-09 Novelty BizCentre, Singapore, SGP, 369585

Website

https://www.biolidics.com

Biolidics Ltd is engaged in technology development, technology transfer, marketing, sale and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are; Cancer, Infectious diseases, Laboratory services, and Corporate. The majority of the company's revenue is generated from the laboratory services segment which involves the business, operation, and provision of laboratory services to customers. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others.

Biolidics Headlines

No Headlines